ArticleNature communications2019
Integrated exome and RNA sequencing of dedifferentiated liposarcoma.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 70 citations in OpenAlex.
- Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.Journal for immunotherapy of cancer · 2026Trial
- Historical contributions and future horizons of Japanese orthopaedic oncology: from surgical innovation to nationwide collaborations.International orthopaedics · 2026Article
- Liposarcoma: State of the Art-A Scoping Review.Medical sciences (Basel, Switzerland) · 2026Article
- RNA-based next-generation sequencing strategy for screening MDM2-amplified sarcomas.Scientific reports · 2026Article
- Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.Science translational medicine · 2026Article
- Histomorphological and molecular characteristics of liposarcoma (Review).Oncology letters · 2025Review
- Exploring the Genetic and Clinical Landscape of Dedifferentiated Endometrioid Carcinoma.International journal of molecular sciences · 2025Article
- Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice.Medical oncology (Northwood, London, England) · 2025Review
- Dedifferentiated Liposarcoma of the Spermatic Cord: A Case Report and Review of the Literature.Cureus · 2025Article
- Bibliometric analysis of liposarcomas treatment from 2004 to 2023.Journal of cancer research and clinical oncology · 2025Article
- Recurrent dedifferentiated liposarcoma with histological grade progression: a case report.Ecancermedicalscience · 2025Article
- Article
- Epigenetic disruption of adipogenic gene enhancers in dedifferentiated liposarcomas and its therapeutic value.Frontiers in oncology · 2025Article
- Gene co-expression network analysis reveals relationship between leukocyte fraction and genomic instability in dedifferentiated liposarcoma.Molecular biology research communications · 2025Article
- Integrated lipidomics and RNA-seq reveal prognostic biomarkers in well-differentiated and dedifferentiated retroperitoneal liposarcoma.Cancer cell international · 2024Article
- Cellular origin and clonal evolution of human dedifferentiated liposarcoma.Nature communications · 2024Article
- Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma.British journal of cancer · 2024Article
- Exploring the biological behavior differences between retroperitoneal and non-retroperitoneal liposarcomas.Heliyon · 2024Article
- Devil in the Dedifferentiated Details: A Rare Case of Primary Pulmonary Dedifferentiated Liposarcoma.Cureus · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
32 authors at 16 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genomic characteristics of dedifferentiated liposarcoma (DDLPS) that are associated with clinical features remain to be identified. Here, we conduct integrated whole exome and RNA sequencing analysis in 115 DDLPS tumors and perform comparative genomic analysis of well-differentiated and dedifferentiated components from eight DDLPS samples. Several somatic copy-number alterations (SCNAs), including the gain of 12q15, are identified as frequent genomic alterations. CTDSP1/2-DNM3OS fusion genes are identified in a subset of DDLPS tumors. Based on the association of SCNAs with clinical features, the DDLPS tumors are clustered into three groups. This clustering can predict the clinical outcome independently. The comparative analysis between well-differentiated and dedifferentiated components identify two categories of genomic alterations: shared alterations, associated with tumorigenesis, and dedifferentiated-specific alterations, associated with malignant transformation. This large-scale genomic analysis reveals the mechanisms underlying the development and progression of DDLPS and provides insights that could contribute to the refinement of DDLPS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.